{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967805",
  "id": "02967805",
  "pages": 6,
  "price_sensitive": false,
  "date": "20250709",
  "time": "1348",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmyw391hd9t2.pdf",
  "summary": "- **Announcement Type**: Placement  \n- **Total Securities Issued**: 17,271 OSL ordinary shares (fully paid)  \n- **Issue Price**: AUD 1.158 per share  \n- **Attaching Securities**: 17,271 options (expiring 31-Jul-2027, exercise price AUD 1.200)  \n- **Purpose**: Funds to be used for clinical trials, administration, and working capital  \n- **Issue Date**: 8-Aug-2025  \n- **Shareholder Approval**: Obtained at EGM on 8-Jul-2025 (related to director participation under SPP terms)  \n\n*Note: No material dilution or underwriting details provided.*",
  "usage": {
    "prompt_tokens": 2175,
    "completion_tokens": 146,
    "total_tokens": 2321,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-09T05:38:40.804012"
}